The project has priority review, but deaths could raise eyebrows.

New first-in-human trials include Kivu and Menarini projects acting on PKT7 and KIF18A.

An in vivo Car-T produced a 100% response rate – in three patients.

Rival BTK degraders face off, as do bispecific Cars and T-cell engagers.

Data will be presented on Kura’s Komzifti and Syndax’s Revuforj in first-line AML.

Five years after settling, GSK is again accused of breaching the Jemperli deal.